Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of OBGEMSA™ (vibegron under the international non-proprietary name) for the symptomatic treatment of adult patients with overactive bladder syndrome (OAB). Pierre Fabre Laboratories acquired an exclusive license from Urovant Sciences to register and commercialize vibegron in the European Economic Area in 2022. OBGEMSA™ is a trademark owned by Urovant Sciences GmbH.

The CHMP recommendation will now be reviewed by the European Commission (EC), which may decide on the marketing authorisation (MA) for OBGEMSA™ (vibegron). The decision will then be applicable to all member states of the European Union as well as to Iceland, Liechtenstein and Norway.

" We are very pleased to have received this positive opinion from the CHMP for OBGEMSA™. If approved, this innovative therapeutic solution has the potential to help patients suffering from overactive bladder, a condition that is very debilitating in daily life. We have been working in the field of urology for more than 40 years and OBGEMSA is proof of our determination to continue our development in this area." said Eric DUCOURNAU, CEO of Pierre Fabre Laboratories.

The CHMP positive opinion is based on positive data from two Phase 3 pivotal, randomized, multicenter and double-blind studies in patients with symptoms of overactive bladder. Study RVT-901-3003 assessed the efficacy, tolerability and safety at 12 weeks of vibegron (at a dose of 75 mg/daily) compared to placebo and tolterodine (as positive control). Its extension, Study RVT-901-3004, assessed the long-term safety, tolerability and efficacy of vibegron at 52 weeks versus tolterodine. In these studies, vibegron, as a new beta-3 adrenergic receptor (ß3 AR) agonist, demonstrated a favourable risk-benefit profile in the symptomatic treatment of urgency, increased micturition and urge urinary incontinence (UUI) that may occur in patients with OAB syndrome.

The CHMP positive opinion is also supported by clinical data from the study URO-901-1001, a randomized, Phase 1, double-blind, placebo-controlled, parallel-group study in subjects with OAB, designed to study the effect of vibegron (at a dose of 75 mg daily or placebo once daily) for a duration of 28 days at steady state on ambulatory blood pressure (BP) and heart rate (HR). Results from this study confirm that vibegron 75 mg had no statistically significant or clinically meaningful effects on Blood Pressure or Heart Rate in patients with symptoms of OAB.